R L P G C M C P W T D *H19*$^{\Delta 13}$

Clive J. Petry,[1] Mark L. Evans,[2,3] Dianne L. Wingate,[1] Ken K. Ong,[1,4] Wolf Reik,[5,6] Miguel Constância,[3,5,6,7] and David B. Dunger[1,3]

H19$^{\Delta 13}$ ... *H19*$^{\Delta 13}$ ... 1, 1 , 1

RESULTS ... 1. ... *H19*$^{\Delta 13}$ ... (1, ± . 1, ± 10 . . $^{-1}$ *P* = 0.01) ... *H19*$^{\Delta 13}$ ... (1, 02 ± 21 = 1 . 1, ± 1 = 1 . $^{-1}$ *P* = 0.00).

CONCLUSIONS ... *H19*$^{\Delta 13}$. ... *IGF2* ...

Diabetes 59:282–286, 2010

... 1002@ ... 20 200 ... 200 ... 0 ... 200 ... 10.2 / 0 -0 ... 2010 ... //- ... / .0/

G ... (1,2) ... ( ) ... ( ) ... ( ). ... ( ). ... (,) ... *H19* ( ), ... *IGF2* ... *H19* ( ), ... *H19*$^{\Delta 13}$ ... 0% ... (10,11).

RESEARCH DESIGN AND METHODS

Animals. ... ( ) 1 ... 2 ... 20 (0), (0) 0. 2 (1). ... 0 (0), (0),







(20),
1 1
2
(21),
( ),
(22).
H19$^{\Delta 13}$ *I 2*
(10,11).
I 2
H19 *91H* (
H19) (2).
I 2
( ).
H19$^{\Delta 13-/+}$
1 1
(2).
I 2 (2), β-
(2),
(1).
H19
( ).
(2).

(10,11)

ACKNOWLEDGMENTS

(0 00)

REFERENCES

1.
200 (. 2) 0 1 1 0
2.
200 1
1 200 .
200 1 2 . 1
1 0
2 200 1 1 21
1 2
1 1 1 1
200
1
200 22
10.
1
11.